Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative
approach in myelofibrosis (MF). Despite advances over recent decades, relapse and non …

The aim of this work is to produce recommendations on the management of allogeneic stem
cell transplantation (allo-SCT) in primary myelofibrosis (PMF). A comprehensive systematic …

Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for
myelofibrosis (MF). In this large multicenter retrospective study, overall survival (OS) in MF …

Summary Allogeneic Haematopoietic Stem Cell Transplant (allo‐HSCT) remains the only
curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the …

Allogeneic haematopoietic stem‐cell transplantation (HSCT) is the only curative treatment
for myelofibrosis. We report an analysis of the Société Française de Greffe de Moelle et de …

New options for medical therapy and risk scoring systems containing molecular data are
leading to increased complexity in the management of patients with myelofibrosis. To inform …

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for
myelofibrosis. Most post-transplantation events occur during the first two years and hence …

The number of patients with myelofibrosis (MF) undergoing an allogeneic hemopoietic stem
cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood …

Background Myelofibrosis is a myeloproliferative stem cell disorder curable exclusively by
allogeneic hematopoietic stem cell transplantation and is associated with substantial …

Myelofibrosis, either de novo or following pre-existing hematologic diseases, can be cured
by allogeneic hematopoietic stem cell transplantation (SCT), but SCT is associated with …